This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

Start Date01 Mar 2029

Sponsor / Collaborator

Womack Army Medical Center

[+1]

NCT06829238

/ RecruitingPhase 4IIT

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use (MET-IH)

This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.

Start Date07 Apr 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT06844487

/ Not yet recruitingPhase 3IIT

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection and complications. The study will compare the safety and immunogenicity of a full-dose regimen versus a half-dose regimen in this population. A hierarchical testing strategy will be applied as follows: first, non-inferiority of the full-dose regimen in infants/children (4-24 months old) will be evaluated against the full-dose regimen in adults from the POX-MVA-045 study. If non-inferiority is demonstrated, the immunogenicity of the half dose in infants/children (4-24 months old) will subsequently be tested for non-inferiority vs the full dose in adult. The trial will be conducted in Boende, Tshuapa Province, DRC.
The trial plans to enroll 344 male and female infants/children, who will be randomized to receive two doses of the MVA-BN vaccine administered 28 days apart. Participants in Child Group 1 (N=172) will receive the standard vaccine dose (0.5 mL), while those in Child Group 2 (N=172) will receive half the standard dose (0.25 mL), with both groups following the same dosing schedule.
This study builds on positive safety and immunogenicity data from prior trials that support the use of the standard dose regimen in younger children. However, considering the developmental differences in the immune systems of infants and young children/adolescents, it aims to evaluate whether a half-dose regimen can provide similar immunogenicity while potentially reducing reactogenicity. The findings will offer valuable insights into the optimal dosing strategy for this age group, balancing safety and immunogenicity to inform future vaccination recommendations.

Start Date31 Mar 2025

Sponsor / Collaborator

University of Antwerp

[+4]

100 Clinical Results associated with Smallpox vaccine(Bavarian Nordic A/S)

100 Translational Medicine associated with Smallpox vaccine(Bavarian Nordic A/S)

100 Patents (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

357

Literatures (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

31 Dec 2025·Virulence

Mpox: Global epidemic situation and countermeasures

Review

Author: Luo, Yinghua ; Jin, Chenghao ; Hou, Wenshuang ; Wu, Nan ; Tang, Yanjun ; Liu, Yanzhi ; Quan, Quan

Mpox, is a zoonotic disease caused by the monkeypox virus and is primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance to the smallpox virus is declining, increasing the risk of infection with mpox and other viruses. On 14 August 2024, the World Health Organization announced that the spread of mpox constituted a public health emergency of international concern. Mpox's transmission routes and symptoms are complex and pose new challenges to global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, and genetically engineered vaccines) and antiviral drugs (such as tecovirimat, brincidofovir, cidofovir, and varicella immunoglobulin intravenous injection) have been developed and marketed to prevent and control this disease. This review aims to introduce the epidemic situation, epidemiological characteristics, physiological and pathological characteristics, and preventive measures for mpox in detail, to provide a scientific basis for the prevention and control of mpox viruses worldwide.

01 May 2025·Lancet Regional Health-Europe

Correction to “Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial” [The Lancet Regional Health—Europe 45, October 2024, 101020]

Author: Rubenstein, Emma ; Molina, Jean-Michel ; Viard, Jean-Paul ; Gibowski, Severine ; Ghosn, Jade ; Costagliola, Dominique ; Pialoux, Gilles ; Ollivier, Manon ; Pavie, Juliette ; Duvivier, Claudine ; Algarte-Genin, Michèle ; Ouattara, Moussa ; Katlama, Christine ; Assoumou, Lambert ; Surgers, Laure

[This corrects the article DOI: 10.1016/j.lanepe.2024.101020.].

15 Apr 2025·JOURNAL OF INFECTIOUS DISEASES

Monkeypox Virus Infection Stimulates a More Robust and Durable Neutralizing Antibody Response Compared to Modified Vaccinia Virus Ankara Vaccination

Article

Author: Selverian, Christopher N ; Meyerowitz, Eric ; DeMouth, Megan E ; Herbert, Andrew S ; Battini, Leandro ; Miller, Emily Happy ; Meola, Annalisa ; Lasso, Gorka ; Berrigan, Jacob ; Jaleta, Yakin M ; Chandran, Kartik ; Guardado-Calvo, Pablo ; Batchelor, Thomas G ; Monticelli, Stephanie R

Abstract:

Monkeypox virus (MPXV) has recently caused a global disease outbreak in humans. Differences in the neutralizing antibody response to vaccination versus MPXV infection remain poorly understood. Here, we examined the neutralization of MPXV and vaccinia virus by sera from a cohort of convalescent and vaccinated individuals at 1 and 8 months postexposure. Convalescent individuals displayed higher neutralizing antibody titers against MPXV than vaccinated and MPXV-naive persons at 1 month postexposure. Neutralizing antibody titers had waned significantly in both groups at 8 months. This study suggests that additional vaccine strategies are needed to elicit a durable humoral response and prevent breakthrough infections.

280

News (Medical) associated with Smallpox vaccine(Bavarian Nordic A/S)

09 May 2025

·www.globenewswire.com

Bavarian Nordic Announces Interim Results for the First Three Months of 2025

COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 52% to DKK 680 million compared to the first quarter of 2024, primarily driven by increased demand for rabies and tick-borne encephalitis (TBE) vaccines.Public Preparedness revenue increased by 83% to DKK 629 million compared to the first quarter of 2024. This exceeded initial expectations due to successful efforts to advance the deliveries of a few, but larger, existing orders into the first quarter.Other revenue was DKK 37 million. The operating profit (EBITDA) was DKK 420 million, corresponding to an EBITDA margin of 31%.Financial guidance for the full year is maintained at a revenue of DKK 5,700-6,700 million and an EBITDA margin of 26-30%. DKK million3m 20253m 20242025 GuidanceRevenue1,3478315,700 – 6,700EBITDA margin31%3%26-30% Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “A very strong first quarter for our Travel Health business, demonstrating a 52% growth year-over-year and puts us ahead of our strategic goal of an average annual growth rate of 10-12% for this part of the business until 2027. We also recorded our first US sales of the chikungunya vaccine after its approval in February and ahead of the April recommendation from ACIP. Our phased launch plan for the vaccine is progressing as planned with the first European markets coming online over the next couple of months while we also continue our efforts to expand the regulatory approvals to other territories. Chikungunya represents an increasing public health threat across the globe, and we are proud to have entered our first partnership to improve access to the vaccine for low- and middle-income countries. In Public Preparedness, we also delivered above expectations. While this was largely due to a number of deliveries occurring ahead of plans, it goes to show the strength and scale of our manufacturing setup to meet the increased demand for our mpox/smallpox vaccine.” Highlights from the first quarter Travel Health Vimkunya was approved in the US and EU in February as the first virus-like particle (VLP)-based chikungunya vaccine and the first chikungunya vaccine for persons aged 12 years and older. Additionally, regulatory submissions were filed in the UK and Canada.Vimkunya was launched commercially in the US in March and will be launched in the first European markets later during the first half of 2025.Concurrently with the US approval of Vimkunya, Bavarian Nordic was granted a Priority Review Voucher, which the Company intends to monetize when appropriate.A strategic partnership was entered with Biological E. Limited in February, initially comprising a contract manufacturing agreement with the aim to provide capacity for the future supply of chikungunya vaccines to endemic low- and middle-income countries. Public Preparedness The freeze-dried version of JYNNEOS was approved by the U.S. Food and Drug Administration (FDA) in March for prevention of smallpox and mpox disease in adults 18 years of age and older. The approval supports the ongoing contract with the US government for stockpiling of the vaccine. Other business In January, Bavarian Nordic launched and completed a share buy-back program of DKK 150 million, with the purpose of adjusting the capital structure. Events after the reporting date In April, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Vimkunya™ for the prevention of disease caused by chikungunya virus for US persons aged 12 and older traveling to regions with an outbreak or elevated risk of chikungunya, as well as for laboratory workers with potential for exposure to chikungunya virus.In May, the UK Medicines and Healthcare products Regulatory Agency granted marketing authorization in the United Kingdom for Vimkunya® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.In May, the US government exercised additional options valued at USD 143.6 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine, with planned delivery in 2026. Conference call and webcastThe management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via https://edge.media-server.com/mmc/p/798tzbob/. To join the Q&A session, please register in advance via https://register-conf.media-server.com/register/BI2a5d49d1c9d64ee99d6d03297d3d4323. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 Company Announcement no. 16 / 2025 About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Attachment Interim Report Q1 2025

Drug ApprovalVaccineFinancial StatementAccelerated ApprovalLicense out/in

09 May 2025

·www.pharmaceutical-technology.com

Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales

Bavarian Nordic has recently secured had key vaccine approvals for chikungunya virus and mpox/smallpox. Image credit: Shutterstock / Anne Czichos. Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from the same period in 2024. The Danish vaccine specialist reported quarterly revenue of DKr1.3bn ($200m), a 62% year-over-year increase. Bavarian Nordic maintained its full year guidance of DKr5.7-DKr6.7bn. Shares in the company opened 7% higher at a price of DKr167.15 at market open, following the announcement made early on 9 May. Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023. Across the first nine months of the fiscal year 2024, the company experienced a 46% deficit. After some key approvals and contract signings, Bavarian Nordic has turned a corner, and its 2025 start makes for some strong financial reading. Revenue for Bavarian Nordic’s travel health business, which includes chikungunya vaccine Vimkunya and rabies shot Rabipur amongst others, increased 52% to Dkr680m. The company stated it was Rabipur and tick-borne encephalitis (TBE) vaccine Encepur that drove the higher sales compared to 2024. Vimkunya was approved in the US and UK in February, becoming the second commercially available jab alongside Valneva’s Ixchiq. Bavarian Nordic could be set for a market advantage as the vaccine is approved for people aged 12 years and older while Ixchiq is only licensed for adults. As of 8 May, Ixchiq is also under review by the European Medicines Agency (EMA) amid reports of serious side effects. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Vimkunya will likely contribute to revenue from Q2 onwards, having been launched in the US in March and set for European markets in H1 2025. Bavarian Nordic received a priority review voucher, which it expects to monetise, as part of Vimkunya’s US approval . Voucher sales have historically averaged at around $100m, facilitating a quick cash injection to biotechs selling them. For its public preparedness business, headed by smallpox/mpox vaccine Jynneos, revenue was up an immense 83% to reach Dkr629m. Bavarian Nordic stated this “exceeded initial expectations” due to orders advanced early into Q1. The company secured a regulatory win when the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Jynneos, supporting the ongoing contract with the US government for stockpiling. This includes recently exercised additional options valued at $144m within the Jynneos stockpiling contract. Vaccines are under the spotlight due to a polarised landscape in the US. Health Secretary Robert F Kennedy, Jr. has voiced anti-vaccine rhetoric and doubled down on scientifically false claims. In a move last week that upped confidence from infectious disease-specialist biotechs, however, the US Department of Health and Human Services (HHS) launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with pandemic potential.

VaccineDrug Approval

06 May 2025

·www.globenewswire.com

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines

Exercised options total USD 143.6 millionSecures manufacturing and supply of freeze-dried JYNNEOS® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 143.6 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine. The options support the manufacturing and supply of freeze-dried JYNNEOS by conversion of bulk vaccine, previously manufactured under other contract options, as well as supplemental payments for all doses procured under the freeze-dried contract, triggered by the demonstration of an extended shelf-life. The supplemental payments will be invoiced pro rata with deliveries of the freeze-dried vaccines. Deliveries under the new contract options are planned for 2026. Bavarian Nordic’s financial guidance for 2025 remains unchanged at total revenues of DKK 5,700-6,700 million and an EBITDA margin of 26-30%. From the Public Preparedness business, revenue of DKK 3,000-4,000 million is still expected, of which DKK 2,650 million has been secured, which is an increase of DKK 150 million following exercise of the options. Paul Chaplin, President & CEO of Bavarian Nordic, said: “Following the recent FDA approval of the freeze-dried formulation of our smallpox/mpox vaccine, we applaud the U.S. government’s steadfast commitment to improving national health security through the exercise of these options. The freeze-dried vaccine, with its improved shelf life, provides a significant contribution to securing the long-term availability of countermeasures to protect U.S citizens against life-threatening diseases.” About our contracts with the U.S. governmentSince 2003, Bavarian Nordic has worked with the U.S. government on the development, manufacturing and supply of a non-replicating smallpox vaccine to ensure all populations can be protected from smallpox and mpox, including people with weakened immune systems who are at high risk of adverse reactions to traditional smallpox vaccines, which are based on replicating vaccinia virus strains. Approved by the FDA in 2019, JYNNEOS was the first smallpox vaccine successfully developed under Project BioShield, a program created by the U.S. Congress in 2004 to accelerate the research, development, procurement, and availability of medical countermeasures against biological, chemical, radiological, and nuclear (CBRN) threats through public-private partnerships. Bavarian Nordic has supplied a liquid-frozen formulation of JYNNEOS to the U.S. government for stockpiling since 2010 and in response to the mpox outbreak in 2022-2023. BARDA has supported the development of a freeze-dried formulation of the vaccine to replenish the stockpile and in 2017 awarded the Company a ten-year contract, which includes options valued at USD 299 million for the fill and finish of freeze-dried vaccines, of which USD 284 million has been exercised to-date. The freeze-dried formulation of JYNNEOS, approved by the FDA in March 2025, provides certain advantages over the liquid-frozen formulation in terms of transportation, storage conditions and shelf life, all of which are important factors for long-term stockpiling. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201700019C. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 Company Announcement no. 15 / 2025 Attachment 2025-15-en

VaccineDrug Approval

100 Deals associated with Smallpox vaccine(Bavarian Nordic A/S)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Smallpox vaccine(Bavarian Nordic A/S)	J07BX	DB15483

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Monkeypox	European Union	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Iceland	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Monkeypox	Norway	Bavarian Nordic A/S	31 Jul 2013
Smallpox	European Union	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Iceland	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Smallpox	Norway	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	European Union	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Iceland	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Liechtenstein	Bavarian Nordic A/S	31 Jul 2013
Vaccinia	Norway	Bavarian Nordic A/S	31 Jul 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	United States	Bavarian Nordic A/S	31 Mar 2025
Dermatitis, Atopic	Phase 2	United States	Bavarian Nordic A/S	01 Jul 2006
Dermatitis, Atopic	Phase 2	Mexico	Bavarian Nordic A/S	01 Jul 2006
HIV Infections	Phase 2	United States	Bavarian Nordic A/S	01 Jun 2006
HIV Infections	Phase 2	Puerto Rico	Bavarian Nordic A/S	01 Jun 2006
Rhinitis, Allergic, Seasonal	Phase 1	Germany	Bavarian Nordic A/S	01 Apr 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05512949 (NEWS) Manual	Phase 2	Monkeypox	229	MVA-BN (aged between 12 and 17 years)	ihdwvnjdvb(qiknqyhjsm) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. aacrjdffne (fkhaeheosd ) View more	Positive	17 Oct 2024
Literature Manual	Not Applicable	Monkeypox	45	MVA-BN 2 doses	gsjkrqwlgt(ccqtojofnk) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months lrqgawpgdy (lemubyfcgz )	Negative	03 Oct 2024
				MVA-BN 1 doses
NCT05740982 (NEWS) Manual	Phase 2	Hemorrhagic Fever, Ebola	526	IMVANEX (adolescents 12-17 years of age)	qirezfeinn(dfmytoiwwg) = a similar safety profile between both age groups enfsypoeck (nkygzohqbu ) View more	Positive	19 Sep 2024
				IMVANEX (adults aged 18 years and older)
NCT05512949 (CTgov)	Phase 2	Monkeypox	229	MVA-BN (2 x 10^7 ID MVA-BN)	cynhemppus(chgrokfglv) = mfbgzaiubl zouqekwigv (hayzndxgdq, vvgbyxtawp - ehbxahrwqp) View more	-	09 Jan 2024
				MVA-BN (1 x 10^7 ID MVA-BN)	cynhemppus(chgrokfglv) = lphdwrseyz zouqekwigv (hayzndxgdq, eyrmpslokx - vechwsueny) View more
NCT03699124 (Pubmed) Manual	Phase 3	-	1,129	MVA-BN	daakvwhzyo(wufmdtsmjb) = tcgozowckg iljgtqrzgl (olzaflosnx ) View more	Positive	29 Nov 2022
NCT03699124 (CTgov)	Phase 3	Smallpox	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	bsugyvfane(kmszdnpcfh) = gfrbmztbpr ezbvagwpsl (wqwfgkazan, kcyjhmaxya - ffrtnqexrj) View more	-	27 May 2021
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	bsugyvfane(kmszdnpcfh) = gxrcbtajxz ezbvagwpsl (wqwfgkazan, yfhbfhucsq - bsfmaqyicx) View more
NCT01668537 (CTgov)	Phase 2	Smallpox	651	LF (LF Formulation)	gcdoturcan(glaucelzeo) = ifkyqljmhm omtnmgiucq (biqlpzvvot, akwtkzevjd - sptplwotyq) View more	-	12 Oct 2020
				MVA-BN (FD Formulation)	gcdoturcan(glaucelzeo) = poyeklnngv omtnmgiucq (biqlpzvvot, iyvtzoilnf - psqlxbqtfc) View more
NCT03472014 (CTgov)	Phase 4	-	22	MVA-BN	zmqhdasznv = nvhtmsdysj fcniyzgxiv (mlgmaahcwb, rjqkkcrbqj - ufyqtzxjmr) View more	-	19 Aug 2020
NCT01913353 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	Smallpox	433	modified vaccinia Ankara+ACAM2000	eaecjqwkry(ihluwkstbl): RO = 97.9 (95% CI, 96.6 - 98.3) View more	Superior	14 Nov 2019
				ACAM2000
NCT00686582 (CTgov)	Phase 2	Smallpox	304	IMVAMUNE (Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose)	cgyjhzmyer = vzypgrtwfa bzccmhroup (jluifxlazh, ipootwvsef - qdjfujwvhl) View more	-	18 Feb 2019
				IMVAMUNE (Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose)	cgyjhzmyer = ppfximpzfc bzccmhroup (jluifxlazh, qjtsaidddi - mgurmtwtkw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Smallpox vaccine(Bavarian Nordic A/S)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation